Women's health and cancer care · November 16 approval

The breast cancer result that can change a treatment conversation

A person living with advanced breast cancer may have a new question for the next oncology appointment: “Does my tumor have the change called ESR1, and does…

  • Kanwar Partap Singh Gill, MD
  • Family medicine physician & independent policy analyst

Published

Sources checked through , 5 p.m. Pacific · facts checked and fully reviewed · 2 min read

A person living with advanced breast cancer may have a new question for the next oncology appointment: “Does my tumor have the change called ESR1, and does that change my options?” On November 16, the FDA approved the combination of giredestrant, sold as Wilserdly, and everolimus for a specific group of adults with advanced disease. It also authorized a companion blood-based test, FoundationOne Liquid CDx, to help identify eligible patients. FDA approval and study results.

Eligibility depends on several findings together. The cancer must be estrogen-receptor positive, HER2-negative, locally advanced or metastatic, and have an ESR1 mutation found with an FDA-authorized test. It must also have returned during or after endocrine-based treatment given after initial treatment, or progressed after at least one endocrine-based regimen for metastatic disease. Someone with a new breast lump or an ordinary screening question follows a different pathway. A blood test for a change in an already diagnosed tumor serves a different purpose from routine screening or a hereditary cancer assessment.

In the randomized trial, 207 of the 373 participants had tumors with ESR1 mutations. In that group the median time before disease progression or death was 10 months with giredestrant plus everolimus and 5.5 months with the comparator endocrine treatment plus everolimus. A median describes groups of patients. It cannot predict the number of months an individual gains. When the FDA reviewed this analysis, overall survival results were still immature. The prescribing information includes warnings about an abnormally slow heart rate and harm to a developing fetus. FDA evidence and safety summary.

For a patient and the physician who sees them between oncology appointments, three details make the conversation easier: the pathology report describing receptor status, any tumor-mutation report, and a list of previous endocrine therapies with the reason each was changed. If the regimen is offered, ask who will review interactions, monitor adverse effects and discuss alternatives. The new option is most meaningful when the patient's own results and treatment history are in front of the team.

Related coverage. Women's health in Fresno across every stage of life · How to organize medical records.

Where this continues on the site

Editorial and informational notice: this analysis of health care, technology, consumer and legal policy is published for education and public awareness. It is not individualized medical, legal or financial advice and does not replace your own clinician, lawyer, bank or benefits office. Court orders, settlements and filings are described for what they decide; allegations are not findings. Kanwar Partap Singh Gill, MD is a physician, not a lawyer, and this site is not a law firm. In an emergency, call 911.

Prepared 19 November 2026 with AI assistance from the sources linked on this page. Facts checked and the page fully reviewed. Evidence cutoff 19 November 2026, 5 p.m. Pacific. Corrections: editorial standards.

Search KPSGill.com

Search the full publication — patient guides, policy, investigations, enforcement records and research.